Clinical trial

A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLD

NCT02285205

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2014-11-01

PhasePHASE4

Study timeline

Study start (unknown)2014-11-01Date precision: month

Registry last updated2016-02-02

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Type 2 Diabetesunresolved

Non-alcoholic Fatty Liver Diseaseunresolved

Interventions

Oral administration of LobeglitazoneDRUG

Sponsors & collaborators

Yonsei Universitylead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02285205 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.